Cary, N.C. – June 28, 2010 – Industry Standard Research (ISR) today announced the release of a new report titled Primer: Physician Biosimilar Prescribing. The report, based on the perspectives of 264 practicing physicians in the United States and the European Union, examines the generic biologics – or biosimilars – market from a commercial perspective. While most research in our industry has taken a development perspective to biosimilars, this report focuses on physicians’ beliefs regarding the safety, efficacy, pricing and other critical characteristics of these potentially complex products. “Because there is no regulatory pathway for approval of these products in the United States, the body of writing on this topic focuses either on the development of biosimilars or on the implications for approval of the products after development”, stated Kevin Olson, President, ISR. “We believe that drug developers and their partners in commercial divisions should also understand what adoption of these products may look like as it may have implications for development strategy and will certainly impact a product’s commercialization strategy. For example, we found that over half of the respondents believe that regulatory authorities should require full-fledged clinical trials for biosimilars as a condition of approval. This was true among both U.S. prescribers and E.U. prescribers and is an indication of prescribers’ levels of comfort with the products.” The report uncovers prescribers’ beliefs toward the pricing of biosimilar products and the implications that pricing will have on their likelihood of prescribing. It also details their attitudes toward pharmacy-level substitution and many other critical indications of trust in these new, complex products. Kevin Olson, President ISR, further explains: “In order to maximize the adoption of biosimilars within the prescribing community, innovator and generics manufacturers need to take in to account this important constituency and we’re confident that this research answers some of the most critical questions.” About Industry Standard Research Industry Standard Research is the premier, full service market research provider to the pharma and pharma services industries. With over a decade of experience in the industry, ISR delivers an unmatched level of domain expertise. For more information about our syndicated and custom research offerings, please visit the company’s Web site at www.ISRreports.com or email info@isrreports.com.

ISR CUSTOMERS